arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GeneDx Holdings Corp.

WGS
$85.24 ▼ -5.64 (-6.21%) at close
Healthcare ·Services-Health Services ·USServices-Health Services
27 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

GeneDx Holdings Corp. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.5B
Dividend Yield
Revenue Growth 11.4%
Op. Margin -15.3%
ROIC -4.9%
FCF / Share $-1.32
Trailing P/E
Price / Book 10.4x
FCF Yield
Debt / Equity 0.41
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$114.44M
↑ +11.4%
Net Income Profit after all expenses
$-17.74M
↑ +72.0%
Operating Margin Operating profit as % of sales
-15.3%
↑ +72.9% 23th
FCF / Share Free cash flow per share
$-1.32
↑ +0.7%
Long-Term Debt Long-term obligations
$100.00M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
27
Returns
37
Financial Health
58
Cash Quality
12

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 27 quarters